+49 30 648 35 164 service@chameleon-pharma.com

Indonesia – TRIUMPH country

With a pop­u­la­tion of 237 mil­lion peo­ple, Indone­sia is the fourth most pop­u­lated coun­try in the world. Within the Pharma mar­ket, it boasts a total annual growth of 13%, and the demand for qual­ity health­care prod­ucts is very high. From 2008 to 2013, Indonesia’s expen­di­tures in the health­care sector increased from US $12.65 bil­lion to approx­i­mately US $26.93 bil­lion.

Con­trary to fore­casts made by numer­ous spe­cial­ists, the lead­ing index IDX has tripled since 2009. The Indone­sian pop­u­la­tion is young, national debts are low, and the gov­ern­ment is ready to increase the flow of money within the health­care sec­tor. The population’s currently low con­sump­tion of Pharma prod­ucts coupled with its growing readi­ness to invest in health­care prod­ucts create an excellent potential for growth; the Indonesian Pharma mar­ket could eas­ily reach approx­i­mately US $11.8 bil­lion by 2015. Fur­ther­more, the Indone­sian gov­ern­ment is will­ing to favour part­ner­ships with for­eign Pharma com­pa­nies, since the domes­tic devel­op­ment of health­care prod­ucts is still at a very low stan­dard.

CPC Press Releases on Indonesia:

Indonesia: A lucrative market